 |
12 Diseases |  |
4 Trials |
|
4 Trials |  |
312 News |  |
| 12345» |
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network. (Pubmed Central) - Sep 11, 2024
The relative benefit of selecting higher efficacy treatments may vary depending on patients' baseline brain atrophy risk. Poor outcomes are predicted in individuals with high baseline risk who are treated with low-efficacy DMTs.
- | Fumaderm (dimethyl fumarate) / Biogen
Biomarker, Journal, Real-world evidence, Real-world: Evaluating the effect of dimethyl fumarate on subclinical biomarkers in a real-world patient cohort. (Pubmed Central) - Aug 7, 2024
Poor outcomes are predicted in individuals with high baseline risk who are treated with low-efficacy DMTs. Results of this real-world study were consistent with previous DMF phase III clinical trials, supporting the generalizability of the effects observed in clinical trials to the real-world clinical setting.
- tofacitinib / Generic mfg.
A case of cutaneous and osteosarcoidosis successfully treated with Tofacitinib (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_5126;
JAK proteins are associated with cell surface cytokine receptors, and so are early mediators of cell response to inflammation whereby STAT driven transcription is initiated. In sarcoidosis, it is predominantly Type 1 inflammatory cytokines and interferon gamma that bind to JAK associated cytokine receptors1.
- | Lemtrada (alemtuzumab) / Sanofi
Retrospective data, Journal: Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis. (Pubmed Central) - Jul 28, 2024
The proportion of pwMS experiencing a moderate/severe relapse and number of relapses declined over pregnancy but increased postpartum. Reinitiation of DMT during the postpartum period was associated with lower risk of relapses, supporting a role for early reinitiation of DMT postpartum.
- ||| Vumerity (diroximel fumarate) / Biogen
P3 data, Journal: Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase (Pubmed Central) - Jul 22, 2024
P3
Reinitiation of DMT during the postpartum period was associated with lower risk of relapses, supporting a role for early reinitiation of DMT postpartum. In EVOLVE-MS-1, after re-baselining at?approximately 7
- | Vumerity (diroximel fumarate) / Biogen
Journal, Lymphopenia: Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. (Pubmed Central) - Jun 27, 2024
P3
In DRF-treated patients in EVOLVE-MS-1, clinical and radiological measurements indicated reduced disease activity regardless of lymphopenia or magnitude of ALC decline from baseline; however, patients who had greater ALC declines appeared to have numerically lower ARR and higher proportions free from relapses and gadolinium-enhancing lesions compared with those with smallest decline. This supports prior evidence that, while lymphopenia may contribute to fumarate efficacy outcomes, it is not the primary mechanism of action.
- | Fumaderm (dimethyl fumarate) / Biogen
Journal, HEOR, Real-world evidence, Real-world: Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase. (Pubmed Central) - May 27, 2024
To use MSBase registry data to compare real-world outcomes in adults with relapsing-remitting MS (RRMS) treated with dimethyl fumarate (DMF) or NSIS (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mitoxantrone or mycophenolate mofetil) between January 1, 2014 and April 1, 2022...The DMF cohort experienced longer times to discontinuation (HR: 0.75; p?=?0.001) and CDP (HR: 0.53; p?=?0.001), and shorter time to CDI (HR: 1.99; p?<?0.008), versus the NSIS cohort. This analysis supports the use of DMF to treat patients with relapsing forms of MS, and may have implications for MS practices in countries where NSIS are commonly used to treat RRMS.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Change in Disease Modifying Therapy from DMF to DRF in People with Multiple Sclerosis and the Impact on CD4/CD8 T Cells (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3938;
PwMS who switched from DMF to DRF showed a statistically significant decrease in CD8 T cell count over 1 year of treatment, with the shift becoming evident after 3 months of treatment. Changes in T cell subsets in patients treated with DRF were not associated with an increase in infections.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_2734;
Changes in T cell subsets in patients treated with DRF were not associated with an increase in infections. Dimethyl fumarate (DMF) and diroximel fumarate (DRF) are disease-modifying therapies for relapsing MS...Similar FUM efficacy was observed in all racial/ethnic subgroups in this analysis of 2150 racial/ethnic minority pwMS, consistent with prior studies.
- || Tysabri (natalizumab) / Biogen, Royalty
Clinical data, Journal: Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies. (Pubmed Central) - Feb 28, 2024
Evaluate long-term clinical outcomes in patients with MS who initiated treatment with either natalizumab or a BRACETD therapy (interferon beta, glatiramer acetate, teriflunomide, or dimethyl fumarate)...The subgroup analysis showed an increased relapse risk as well as a significantly higher risk of CDW for BRACETD patients. Early initiation of natalizumab produced long-term benefits in relapse outcomes in comparison with BRACETD, regardless of a subsequent escalation in therapy.
- | Tysabri (natalizumab) / Biogen, Royalty, Fumaderm (dimethyl fumarate) / Biogen
Journal, HEOR: Visualizing the target estimand in comparative effectiveness studies with multiple treatments. (Pubmed Central) - Feb 2, 2024
Early initiation of natalizumab produced long-term benefits in relapse outcomes in comparison with BRACETD, regardless of a subsequent escalation in therapy. We showcase how these visualization tools can facilitate the interpretation of target estimands in a case study comparing the effectiveness of teriflunomide (TERI), dimethyl fumarate (DMF)
- | Fumaderm (dimethyl fumarate) / Biogen
Journal: Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry. (Pubmed Central) - Jan 3, 2024
Adjudicator-confirmed EUROCAT birth defects were found in 2.2%. DMF exposure during pregnancy did not adversely affect pregnancy outcomes; birth defects, preterm birth, and spontaneous abortion were in line with rates from the general population.
- | Tysabri (natalizumab) / Biogen, Royalty
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. (Pubmed Central) - Dec 12, 2023
Real-world data from the MSBase Registry were obtained for patients with RES-RRMS who were previously either naive to disease-modifying therapies or had been treated with interferon-based therapies, glatiramer acetate, dimethyl fumarate, or teriflunomide (collectively known as BRACETD)...Similar cost-effectiveness results were observed across sensitivity analyses. This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.
- ||| Vumerity (diroximel fumarate) / Biogen
P3 data, Journal: Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. (Pubmed Central) - Nov 30, 2023
DRF was generally well tolerated over 2 years, with few discontinuations due to AEs; radiological measures indicated decreased disease activity from baseline. These outcomes support DRF as a treatment option in patients with RRMS.
- || dimethyl fumarate / Generic mfg., Fumaderm (dimethyl fumarate) / Biogen
P4 data, Journal: Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial. (Pubmed Central) - Oct 22, 2023
Notably, particular miRNAs correlated with high or low NFL levels, implying their potential role as markers of treatment efficacy. Our findings broaden the understanding of DMF's immunomodulatory effects and may aid in predicting treatment responses.
- | Vumerity (diroximel fumarate) / Biogen
Journal, Real-world evidence, Adherence, Real-world: Response to Letter to the Editor Regarding "Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis". (Pubmed Central) - Sep 14, 2023
Our findings broaden the understanding of DMF's immunomodulatory effects and may aid in predicting treatment responses. No abstract available
- || Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Review, Journal: Vaccine response in people with multiple sclerosis treated with fumarates. (Pubmed Central) - Sep 11, 2023
The fumarates, dimethyl fumarate, diroximel fumarate, and monomethyl fumarate, are approved for the treatment of relapsing multiple sclerosis...Additionally, no increase in relapse has been observed in pwMS following vaccination. In pwMS receiving fumarates, vaccination is generally safe and elicits protective immune responses.
- | Fumaderm (dimethyl fumarate) / Biogen
Journal, HEOR: Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry. (Pubmed Central) - Aug 29, 2023
A MS patient subgroup was identified for whom DMF was more effective than TERI (p?=?0.013): older (45 versus 38 years), longer MS duration (110 versus 50 months), not newly diagnosed (74% versus 40%), and no prior glatiramer acetate usage (35% versus 5%). The implemented approach can disentangle prognostic differences from treatment effect heterogeneity and provide unbiased patient-specific profiling of comparative effectiveness based on real-world data.
- | Fumaderm (dimethyl fumarate) / Biogen
Retrospective data, Journal, HEOR, Real-world evidence, Real-world: Handling related publications reporting real-world evidence in network meta-analysis: a case study in multiple sclerosis. (Pubmed Central) - Jul 29, 2023
An a priori hierarchy should guide the selection among related publications in NMAs of RWE. Sensitivity analyses modifying the hierarchy should be considered for networks with few or small studies.
- | Tysabri (natalizumab) / Biogen, Royalty, Fumaderm (dimethyl fumarate) / Biogen
Journal, MRI: Assessing the utility of magnetic resonance imaging-based "SuStaIn" disease subtyping for precision medicine in relapsing-remitting and secondary progressive multiple sclerosis. (Pubmed Central) - Jul 17, 2023
Sensitivity analyses modifying the hierarchy should be considered for networks with few or small studies. SuStaIn subtypes correlated with disease severity and functional impairment at baseline but were not predictive of disability progression and could not discriminate treatment response heterogeneity.
- | Fumaderm (dimethyl fumarate) / Biogen
Waarom wordt fumaderm niet (meer?) voorgeschreven? (Twitter) - May 27, 2023
- Fumaderm (dimethyl fumarate) / Biogen
A necrobiotic disorder with limited response to numerous systemic therapies (Level 3 - Room 323) - Apr 24, 2023 - Abstract #WCD2023WCD_696;
KEY POINTS: Perforating granuloma annulare is a rare subtype with a prevalence of 5% of granuloma annulare and 80% of patients are younger than 30 years (1). Histologically perforating transepithelial necrobiotic material can be seen and is recognised in perforating granuloma annulare (2), however, this can be difficult to differentiate from other conditions including cutaneous sarcoidosis and mycobacterial infection
- Tysabri (natalizumab) / Biogen, Royalty, Fumaderm (dimethyl fumarate) / Biogen, Ocrevus (ocrelizumab) / Roche, Biogen
Patterns of Disease Modifying Therapy Utilization in Women with Multiple Sclerosis Before, During, and After Pregnancy (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3187;
Conclusions DMT utilization declined sharply during pregnancy; it gradually increased postpartum but remained below pre-pregnancy use. Infusibles administered every 6-12 months (e.g., anti-CD20 medications) may have been underestimated.
- Vumerity (diroximel fumarate) / Biogen
Diroximel Fumarate Pregnancy Outcomes in EVOLVE-MS-1 and Study Design of Diroximel Fumarate Prospective MS Pregnancy Exposure Registry (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3174;
P3
It is important to better understand potential pregnancy-related risks associated with use of DRF to help providers and patients with medical decision-making. The BlossoMS registry will provide essential information on the risk of birth defects, congenital abnormalities, and pregnancy outcomes among women with MS exposed to DRF during pregnancy.
- Fumaderm (dimethyl fumarate) / Biogen
Final Analysis of Pregnancy Outcomes Following Exposure to Dimethyl Fumarate in a Prospective International Registry (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_3112;
P=N/A
Overall, 13 (3.6%) infants had adjudicator-confirmed MACDP birth defects and 8 (2.2%) had adjudicator-confirmed EUROCAT birth defects. Conclusions Dimethyl fumarate exposure during pregnancy did not adversely affect pregnancy outcomes, with no increased incidence of birth defects and no increased rate of spontaneous abortion.
- Vumerity (diroximel fumarate) / Biogen
Male MS Patients' Safety, Tolerability and Efficacy Outcomes Do Not Differ from Female Patients Treated with Diroximel Fumarate: EVOLVE-MS-1 Ad-hoc Analysis (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2837;
P3
Conclusions After 2 years of DRF exposure, both male and female patients with MS had similar safety, tolerability, and efficacy outcomes. These data suggest that, despite males tending to experience more aggressive disease, DRF is a suitable treatment strategy for this patient cohort.
- Vumerity (diroximel fumarate) / Biogen
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 after Re-baselining in the Phase 3 EVOLVE-MS-1 Study (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2821;
P3
Safety outcomes were consistent with those previously reported for EVOLVE-MS-1; discontinuations due to adverse events were low. Re-baselining may be useful for assessing DRF efficacy by mitigating the influence of disease activity prior to the onset of efficacy.
- Fumaderm (dimethyl fumarate) / Biogen
Long-Term Safety and Effectiveness of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice, an updated analysis of the ESTEEM Study (Both in-person and online) - Mar 12, 2023 - Abstract #AAN2023AAN_2654;
P=N/A
Similarly, relapse rates were low and both ARR and PROs remained stable over time. This indicates a sustained effectiveness for patients who remain on DMF treatment for up to 5 years.
- || dimethyl fumarate / Generic mfg., Fumaderm (dimethyl fumarate) / Biogen
Clinical, Journal: Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. (Pubmed Central) - Mar 2, 2023
P4
This is the first randomized clinical trial demonstrating the benefit of a disease-modifying therapy in preventing a first acute clinical event in people with RIS. ANN NEUROL 2023;93:604-614.
- | Fumaderm (dimethyl fumarate) / Biogen
Journal: Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study. (Pubmed Central) - Feb 14, 2023
In patients with relapsing-remitting multiple sclerosis, the treatment with dimethyl fumarate was associated with improvements in patient-reported quality of sleep. Further randomised clinical trials are needed to confirm the benefits of long-term treatment with dimethyl fumarate.
- | Fumaderm (dimethyl fumarate) / Biogen
Journal: Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis. (Pubmed Central) - Feb 12, 2023
In subjects reporting side effects, a higher abundance of Streptococcus, Haemophilus, Clostridium, Lachnospira, Blautia, Subdoligranulum, and Tenericutes and lower of Bacteroidetes, Barnesiella, Odoribacter, Akkermansia, and some Proteobacteria families were detected. Our results suggest that gut microbiota may be involved in therapeutic action and side effects of DMF, representing a potential target for improving disease course and DMT tolerability.
- Tysabri (natalizumab) / Biogen, Royalty, Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
Impact of Immunomodulatory Therapies Natalizumab, Diroximel Fumarate and Dimethyl Fumarate on Cellular and Humoral Immune Response to SARS-CoV-2 in MS Patients (Pacific Ballroom) - Feb 7, 2023 - Abstract #ACTRIMSForum2023ACTRIMS_Forum_431;
Our results suggest that gut microbiota may be involved in therapeutic action and side effects of DMF, representing a potential target for improving disease course and DMT tolerability. Abstract is embargoed at this time.
- | Fumaderm (dimethyl fumarate) / Biogen
Journal: Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate. (Pubmed Central) - Nov 18, 2022
Lymphopenia is the common risk for PML in DMF treatment. DMF-related PML is rare but has occurred in the setting of lymphopenia, supporting the current recommendations for absolute lymphocyte count monitoring in all patients, regardless of age and time on therapy.
- | Vumerity (diroximel fumarate) / Biogen
Journal, Real-world evidence: Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis. (Pubmed Central) - Nov 6, 2022
Of 433 patients who switched from DMF to DRF, most (> 90%) were able to tolerate and persist on DRF after switching. Graphical abstract available for this article.
- Vumerity (diroximel fumarate) / Biogen
Flushing and Gastrointestinal Adverse Event Analysis from the Phase 3 EVOLVE-MS-1 Study of Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1762;
P3
Four (<1%) patients discontinued DRF due to flushing/flushing-related AEs and five (<1%) patients discontinued due to GI AEs. These data are consistent with the known safety profile of DRF.
- Fumaderm (dimethyl fumarate) / Biogen
Assessing the Impact of US Patient Support Programmes on Relapsing-Remitting MS Patients on Dimethyl Fumarate (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1240;
A higher number of consultations with a physiotherapist suggests that patients on a PSP could be more engaged in their treatment and access more services. Initiating treatments with access to a PSP for patients may have some additional benefits and value beyond the effects of the drug alone.
- Vumerity (diroximel fumarate) / Biogen
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Final Safety and Efficacy Results from the Phase 3 EVOLVE-MS-1 Study (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_995;
P3
While 22.8% of patients discontinued DRF, discontinuations due to GI AEs (0.7%) and flushing (0.5%) were low. ARR on DRF was low; MRI showed decreases in disease activity.
- Tysabri (natalizumab) / Biogen, Royalty
SISTER – Subcutaneous: Non-interventional, observational, prospective, German multicentre, open label study over 12-months for Tysabri Patient Preference – Experience from Real World – Preliminary results of the 1st interim analysis (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_847;
The most frequent MS therapies prior to NTZ were fingolimod (23 pts, 20.7%), dimethyl fumarate (18 pts, 16.2%), and glatiramer acetate (17 pts, 15.3%)... This study will provide valuable insight into patients’ preference for NTZ ROA in routine care and complement currently available data from clinical studies with real-world data on subcutaneous natalizumab.
- || Fumaderm (dimethyl fumarate) / Biogen
Clinical, Journal: Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial. (Pubmed Central) - Oct 5, 2022
P3
DMF was well tolerated. ClinicalTrials.gov Identifier: NCT02283853.
- | Fumaderm (dimethyl fumarate) / Biogen
Journal, HEOR: Overall and patient-level comparative effectiveness of dimethyl fumarate and fingolimod: A precision medicine application to the Observatoire Français de la Sclérose en Plaques registry. (Pubmed Central) - Aug 13, 2022
None of the five precision medicine scoring approaches identified treatment heterogeneity. These findings substantiated the similar effectiveness and different discontinuation profiles for dimethyl fumarate and fingolimod as a second-line therapy for relapsing-remitting multiple sclerosis, with no significant effect heterogeneity observed.
- Vumerity (diroximel fumarate) / Biogen
Real-World Analysis Affirms High Persistence and Adherence with Diroximel Fumarate after Switch from DMF to DRF in MS (B1) - Jul 18, 2022 - Abstract #EAN2022EAN_2430;
These findings substantiated the similar effectiveness and different discontinuation profiles for dimethyl fumarate and fingolimod as a second-line therapy for relapsing-remitting multiple sclerosis, with no significant effect heterogeneity observed. Of 433 patients who switched from DMF to DRF, most (>90%) were able to tolerate and persist on DRF after switching; patients also had a high rate of adherence to DRF, with low treatment discontinuation due to GI AEs.
- | Vumerity (diroximel fumarate) / Biogen
Journal, HEOR, Interview: Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews. (Pubmed Central) - Jul 1, 2022
Overall wellness, ease of administration, and minimal and manageable side effects were DRF-related concepts most meaningful to patients on therapy. Acknowledging these patient perceptions in shared decision-making may lead to greater patient adherence and optimal treatment outcomes.
- | Fumaderm (dimethyl fumarate) / Biogen, Ocrevus (ocrelizumab) / Roche, Biogen
Retrospective data, Journal, HEOR: Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab. (Pubmed Central) - Jun 29, 2022
Acknowledging these patient perceptions in shared decision-making may lead to greater patient adherence and optimal treatment outcomes. DMF-treated patients PS-matched with OCR patients experienced lower annualized rates of infection encounters and lower infection-related HCCs.
- Vumerity (diroximel fumarate) / Biogen
Diroximel Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Interim Safety and Efficacy Results from the Phase 3 Evolve-MS-1 Study (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_80;
P3
Clinical and radiological (Gd+ lesion counts) outcomes significantly improved, and no discontinuations due to GI AEs were seen. These data suggest that DRF is an effective treatment option for young adults with MS.
- Fumaderm (dimethyl fumarate) / Biogen
Real-World Effectiveness and Safety after 5 Years of Dimethyl Fumarate Treatment in Black/African American and Hispanic/Latino American Patients with Multiple Sclerosis in Esteem (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_69;
Compared with the 12 months before DMF initiation, ARR was significantly lower up to 5 years after DMF initiation in Black/AA and H/L patients. DMF’s safety profile in these subgroups was consistent with the overall ESTEEM population, although lymphopenia was less pronounced in black/AA and H/L subgroups; these lymphocyte findings should be interpreted with caution as this study was not designed to compare lymphocyte changes between different patient subgroups.
- Vumerity (diroximel fumarate) / Biogen
Patient Experience on Diroximel Fumarate (DRF) from the Mymsteam Social Network: Considerations for Dmt Selection (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_67;
However, the decision to remain on a treatment is determined by efficacy and tolerability. Early real-world data suggest that DRF is well tolerated and the majority of DRF patients reported experiencing physical benefits.
- Immune Response to COVID-19 Vaccine in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_64;
The relative importance of both humoral and cell-mediated immunity to SARS-CoV-2 in the context of DMTs is crucial to understand, especially for PwMS who failed to seroconvert. Study Support: Biogen.
- Vumerity (diroximel fumarate) / Biogen
Characterizing Early Real-World Experience of Narcoms Registry Participants Treated with Diroximel Fumarate (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_33;
No discontinuations due to GI side effects were observed. The effects of DRF on disability progression and patient-reported outcomes will be followed longitudinally.
- ||| Vumerity (diroximel fumarate) / Biogen
P3 data, Journal: Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study. (Pubmed Central) - Apr 12, 2022
P3
Efficacy in patients with prior GA or IFN treatment was consistent with previous fumarate studies. The data suggest that transition to DRF from GA, IFN, or DMF is a reasonable treatment strategy, with low rates of discontinuation due to GI AEs.
- || Fumaderm (dimethyl fumarate) / Biogen
Clinical, Journal: Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. (Pubmed Central) - Apr 6, 2022
Over 10 years, 72% DMF/DMF and 73% PBO/DMF had no 24-week confirmed disability worsening. Sustained DMF safety/efficacy was observed in patients followed up to 13 years, supporting DMF's positive benefit/risk profile for long-term RRMS treatment.